Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Merkel Cell 6Neoplasm Metastasis 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Urethral Neoplasms 1Ureteral Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Penile Squamous Cell Carcinoma (PSCC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Radiotherapy 3fludarabine 2Cyclophosphamide 2pembrolizumab 1olaparib 1envafolimab 1avelumab 1Sunitinib 1Radiotherapy, Adjuvant 1Nivolumab 1Etoposide 1Drug Therapy 1Cisplatin 1Chemoradiotherapy 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymoma × avelumab × 90 days × Clear all
NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡